Comparison of Mortality Risk Associated With Bacteremia Due to Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus

Objective. To quantify the clinical impact of methicillin-resistance in Staphylococcus aureus causing infection complicated by bacteremia in adult patients, while controlling for the severity of patients' underlying illnesses. Design. Retrospective cohort study from October 1, 1995, through December 31, 2003. Patients and Setting. A total of 438 patients with S. aureus infection complicated by bacteremia from a single Veterans Affairs healthcare system. Results. We found that 193 (44%) of the 438 patients had methicillin-resistant S. aureus (MRSA) infection and 114 (26%) died of causes attributable to S. aureus infection within 90 days after the infection was identified. Patients with MRSA infection had a higher mortality risk, compared with patients with methicillin-susceptible S. aureus (MSSA) infections (relative risk, 1.7 [95% confidence interval, 1.3-2.4]; P < .01), except for patients with pneumonia (relative risk, 0.7 [95% confidence interval, 0.4-1.3]). Patients with MRSA infections were significantly older (P < .01), had more underlying diseases (P = .02), and were more likely to have severe sepsis in response to their infection (P < .01) compared with patients with MSSA bacteremia. Patients who died within 90 days after S. aureus infection was identified were significantly older (P < .01) and more likely to have severe sepsis (P < .01) and pneumonia (P = .01), compared with patients who survived. After adjusting for age as a confounder, comorbidities, and pneumonia as an effect modifier, S. aureus infection-related mortality remained significantly higher in patients with MRSA infection than in those with MSSA infection, among those without pneumonia (hazard ratio, 1.8 [95% confidence interval, 1.2-3.0]); P < .01. Conclusions. The results of this study suggest that patients with MRSA infections other than pneumonia have a higher mortality risk than patients with MSSA infections other than pneumonia, independent of the severity of patients' underlying illnesses.

[1]  C. Clec’h,et al.  Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  T. Lodise,et al.  Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. , 2005, Diagnostic microbiology and infectious disease.

[3]  H. Rüden,et al.  Mortality Risk Factors with Nosocomial Staphylococcus aureus Infections in Intensive Care Units: Results from the German Nosocomial Infection Surveillance System (KISS) , 2005, Infection.

[4]  S. Cosgrove,et al.  The Impact of Methicillin Resistance in Staphylococcus aureus Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges , 2005, Infection Control &#x0026; Hospital Epidemiology.

[5]  A. Combes,et al.  Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. , 2004, American journal of respiratory and critical care medicine.

[6]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[7]  C. Woods,et al.  Clinical identifiers of complicated Staphylococcus aureus bacteremia. , 2003, Archives of internal medicine.

[8]  J. Hurley.  Comparison of mortality associated with methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: an ecological analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Oh,et al.  Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  D. Christmann,et al.  Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. , 2003, Infection control and hospital epidemiology.

[11]  M. Rybak,et al.  Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  H. Davies,et al.  Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. , 2003, The Journal of infectious diseases.

[13]  F. Colardyn,et al.  Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. , 2002, Archives of internal medicine.

[14]  M. Whitby,et al.  Nosocomial Methicillin-Resistant Staphylococcus aureus Bacteremia: Is It Any Worse Than Nosocomial Methicillin-Sensitive Staphylococcus aureus Bacteremia? , 2000, Infection Control &#x0026; Hospital Epidemiology.

[15]  M Maclure,et al.  Use of comorbidity scores for control of confounding in studies using administrative databases. , 2000, International journal of epidemiology.

[16]  Nnis System,et al.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. , 1999, American journal of infection control.

[17]  M. González,et al.  Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  G. Gottlieb,et al.  Staphylococcus aureus bacteremia among elderly vs younger adult patients: comparison of clinical features and mortality. , 1999, Archives of internal medicine.

[19]  J. Romero-Vivas,et al.  Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Durack,et al.  New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. , 1994, The American journal of medicine.

[21]  I. L. Cohen.  Guidelines for the use of innovative therapies in sepsis. , 1993, Critical care medicine.

[22]  J. Concato,et al.  The Risk of Determining Risk with Multivariable Models , 1993, Annals of Internal Medicine.

[23]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[24]  B. R. Reddy,et al.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. , 1991, Annals of internal medicine.

[25]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[26]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[27]  L. Saravolatz,et al.  Comparison of methicillin-resistant and methicillin-sensitive Staphylococcus aureus bacteremia. , 1985, American journal of infection control.

[28]  M. Sande,et al.  Staphylococcus aureus Endocarditis: Clinical Manifestations in Addicts and Nonaddicts , 1983, Medicine.

[29]  M. Sande,et al.  Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. , 1982, Annals of internal medicine.

[30]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .

[31]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  A. Castelo,et al.  Risk factors for mortality in Staphylococcus aureus bacteremia. , 1998, Infection control and hospital epidemiology.

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[34]  N. Breslow,et al.  The analysis of case-control studies , 1980 .